Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology
Xenetic Biosciences, Inc. to Present at NobleCon17
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology
Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
